January 2019 in “Research Square (Research Square)” In this study, researchers will conduct a randomized, double-blind, multi-center clinical trial to assess the effectiveness of YH0618 granule in preventing chemotherapy-induced hair loss among breast cancer patients, aiming to understand its mechanism related to kidney deficiency in Chinese Medicine. Results are not yet reported.
September 2022 in “Concilium” This study found that scalp cooling effectively prevented chemotherapy-induced alopecia in patients, with a higher success rate observed in those who did not receive anthracyclines, although some experienced scalp pain and other mild adverse effects.
June 2026 in “Pathology & Oncology Research” In this study, the Orbis PAXMAN® scalp cooling system showed effectiveness and good tolerability in preventing chemotherapy-induced hair loss in breast cancer patients, particularly those receiving anthracycline-free chemotherapy, though the presence of comorbidities was linked to a higher risk of severe alopecia.
August 2026 in “PLoS ONE” This study will evaluate the clinical efficacy, patient-reported outcomes, and economic impact of the PAXMAN® PSCS 2 automated scalp cooling system versus standard cold-cap therapy to prevent chemotherapy-induced hair loss in women with localized breast cancer during anthracycline and taxane treatment.
168 citations
,
December 1986 in “Cancer Chemotherapy and Pharmacology” Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.